Background: Complement activation plays a role in pathogenesis of the antiphospholipid syndrome (APS), but the involvement of the C5b-9 membrane attack complex (MAC) is unknown. Here we studied the effects of human polyclonal antiphospholipid (aPL) antibodies on thrombosis and tissue factor (TF) up-regulation in C6 deficient (C6 À/À ) mice. Methods: C6 À/À mice or the wild-type C3H/HeJ (C6 þ/þ ) mice were injected twice with IgG-APS (n ¼ 2) or IgM-APS (n ¼ 1) isolated from APS patients or with the corresponding control immunoglobulins (Igs) of normal human serum, (NHS) (IgG-NHS or IgM-NHS). Then, the sizes of induced thrombi in the femoral vein were determined 72 hours after the first injection. Tissue factor was determined in homogenates of carotid arteries and in peritoneal macrophages. Results: Thrombus sizes were significantly larger in C6 þ/þ treated with IgG-APS1 or with IgG-APS2 or with IgM-APS when compared with C6 þ/þ mice treated with IgG-NHS or with IgM-NHS, respectively. The sizes of thrombi were significantly smaller in the C6 À/À mice injected with IgG-APS1, IgG-APS2 or IgM-APS (p < 0.001), compared to their C6 þ/þ counterparts showing an important abrogation of thrombus formation in mice lacking C6. The TF expression and activity in the C6 À/À mice treated with IgG-APS or IgM-APS were diminished when compared to C3H/HeJ (C6 þ/þ ) mice treated with the same Igs. All mice injected with IgG-APS and IgM-APS had medium-high titers of anticardiolipin (aCL) and anti-b 2 glycoprotein I (ab 2 GPI) antibodies. Conclusions: These data indicate that the C6 component of the complement system mediates aPL-thrombogenic effects, underscoring an important pathogenic mechanism and indicating the possibility of inhibiting complement to ameliorate APS-related manifestations. Lupus (2012) 21, 1497-1505.
Introduction
The antiphospholipid syndrome (APS) is a systemic autoimmune and inflammatory disease characterized by hypercoagulability, venous and/or arterial thromboses, pregnancy morbidity, in association with antiphospholipid (aPL) antibodies, namely anticardiolipin (aCL) antibodies and/or antib 2 glycoprotein I (ab 2 GPI) antibodies and/or a positive lupus anticoagulant (LA) test. 1, 2 The pathogenic mechanisms of aPL-induced thrombosis are not completely understood. APL antibodies are a heterogeneous group of antibodies that have been shown to be pathogenic in vitro and in vivo. 3 Passive transfer of IgG from aPL-positive sera (IgG-APS) has been found to induce fetal loss, thrombosis and endothelial cell (EC) activation in mice, suggesting a direct pathogenic role. [3] [4] [5] The data strongly suggest that in vitro aPL antibodies induce a pro-inflammatory and pro-coagulant effect on ECs and monocytes, as measured by expression of TF and adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1) and E-selectin (E-sel) and platelets (enhanced activation and aggregation, thromboxane production, etc) and that these effects are mediated by p38 mitogen activated protein kinase (p38MAPK) in ECs, in monocytes and in platelets. 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] These effects also require activation of nuclear factor-kB (NF-kB) in ECs and monocytes and involve the direct interaction of b 2 GPI/aPL complexes with membrane receptors (i.e. TLR-4, annexin A2, apolipoprotein E receptor 2 (APOER2), etc). [16] [17] [18] [19] [20] [21] Two complement effect or pathways are initiated by cleavage of C5: C5a and C5b, which leads to formation of the C5b-9 MAC. It is well established that activated complement fragments themselves have the capacity to bind and activate ECs, as well as to induce a prothrombotic phenotype either directly through C5b-9 MAC or through C5a receptor (C5aR)-mediated effects. 22 ,23 Furthermore C5a and the C5b-9 MAC complex have been shown to bind to ECs and to induce TF expression and exert procoagulant effects. 24, 25 In addition, both complement products have been shown to activate NF-kB and p38 MAPK in various cell types. 26, 27 Studies performed in rats have shown that CD59, an inhibitor of C5b-9 assembly and insertion, serves a protective role in a rat model of thrombotic microangiopathy, demonstrating that C5b-9 plays a critical role in the pathogenesis of thrombosis. 28 Complement activation -involving specifically C3 and C5 -has been shown to contribute to aPL-mediated thrombosis and pregnancy loss in mice. [29] [30] [31] [32] [33] [34] In previous studies, our group showed that C5 activation is required for aPL-mediated thrombogenic and pro-inflammatory effects in vivo, utilizing C3 and C5 and C5a receptor deficient mice and an anti-C5 monoclonal antibody (anti-C5MoAb). 30, 32 These effects were seen only when injecting in the mice complement-fixing aPL antibodies. 32 However, whether C5b-9 MAC mediates aPL-prothrombotic effects in vivo is not known. Hence, here we addressed that question by examining whether thrombus formation and TF upregulation induced by aPL antibodies are affected in C6 deficient À/À (C6 À/À ) mice treated with human polyclonal IgG or IgM aPL antibodies isolated from APS patients.
Material and methods
Purification and characterization of immunoglobulins with APL activity and controls Sera from three individuals with primary APS who fulfilled the Sapporo revised criteria 2 were used to isolate two IgG inmunoglobulins (IgG-APS1, IgG-APS2) and one IgM immunoglobulin (IgM-APS) with aCL and ab 2 GPI activity. IgG-APS1 were obtained from the serum of a 58-year-old patient who had a history of three episodes of deep vein thrombosis and catastrophic antiphospholipid syndrome (CAPS). His aCL titer was 134 G phospholipid units (GPL) and 135 standard G units (SGU), and he was positive for LA. IgG-APS2 was obtained from the serum of a 34-year-old female patient who had CAPS. Her aCL titer was 125 GPL and her ab 2 GPI titer was 203 SGU units and she was LA positive. IgM-APS was obtained from a 33-yearold female patient who had a history of pregnancy losses. Her aCL titer was 189 standard M phospholipid units (MPL) and her ab 2 GPI titer was 203 standard M units (SGM) and she was also LA positive. Pooled sera from ten (n ¼ 10) healthy donors (normal human serum, (NHS)) was used as source of control IgG and IgM (IgG-NHS and IgM-NHS, respectively). All research subjects who donated serum signed an informed consent that was approved by the Institutional Review Board of the University of Texas Medical Branch.
IgG-APS, IgG-NHS, IgM-APS and IgM-NHS were isolated from the serum of patients and controls by ion exchange chromatography using a DEAE-Sepharose CL-6B column (GE Healthcare Bio-Sciences Corp, Piscataway, New Jersey, USA), as described elsewhere. 10 The isolated IgG and IgM fractions were determined to be free of endotoxin contamination by the limulus amebocyte lysate assay (E-toxate; Sigma-Aldrich Co, St. Louis, Missouri, USA). Protein concentrations were determined by the Bradford method. 35 Finally, the aCL and ab 2 GPI activities in human sera, in the isolated human Igs and in the sera of the mice after treatment, were determined using an in house method for the aCL (the result were expressed in standard GPL and MPL units) 36 and by using a commercial kit for the detection of ab 2 GPI antibodies (INOVA Diagnostics, Inc., San Diego, California, USA) (the results were expressed in SGU and SMU units).
The complement fixing activities of the IgG-APS, IgM-APS or IgG-NHS, IgM-NHS were determined by ELISA as described. 37 Briefly, the Ig fractions were incubated onto a plate coated with b 2 GPI followed by addition of purified C1q (Quidel, San Diego, California, USA) at the concentration of 20 mg/mL for 60 minutes at 37 C. Then, the bound C1q was detected by its reaction with goat anti-C1q IgG labeled with biotin followed by alkaline phosphatase-streptavidin labeled rabbit anti-goat IgG (Sigma-Aldrich). The results are expressed as mean of optical density (OD) values. The mean of OD values of the control group did not exceed 0.3.
In vivo experiments: analysis of thrombus dynamics
C6 À/À mice were kindly provided by Drs Salmon and Girardi (Cornell University, New York, USA). Wild type C3H/HeJ (C6 þ/þ ) mice were purchased from Jackson Laboratories (Bar Harbor, Massachusetts, USA). All the animals were handled by trained personnel according the Institutional Animal Care and Use Committee guidelines and housed in the animal care facilities of the University of Texas Medical Branch. Mice weight was approximately 20 g.
Five animals per group were injected intraperitoneally (i.p.) twice (at time 0 and 48 hours later) with 500 mg of IgG-APS or IgM-APS, or with the corresponding controls (IgG-NHS or IgM-NHS). Surgical procedures were performed to study thrombus dynamics 72 hours after the first injection.
Analysis of thrombus dynamics in the mice was assessed as described elsewhere after treatment. 3, 6, 10, 16, [19] [20] [21] 30, 32, 38 Briefly, mice were anesthetized and the right femoral vein was exposed and pinched using a standard pressure to introduce injury. Clot formation and dissolution in the trans-illuminated vein were visualized and recorded with a microscope attached to a close-circuit video system. Two to three thrombi times were induced in each animal, and the thrombus area was computed for each group of animals. Thrombus sizes were expressed in mm 2 . At the end of the surgical procedures a sample of blood was obtained from the mice to determine the aCL and ab 2 GPI titers, as described in the previous section.
Tissue factor activity in carotid homogenates and peritoneal macrophages
At the end of the surgical procedures, uninjured carotids were dissected and collected from each animal and placed into Tris-buffered saline-0.01% Triton X-100 buffer containing heparin. 39 Peritoneal macrophages were collected by flushing the peritoneal cavity with phosphate buffered saline solution (PBS) for five minutes.. Then, carotids and macrophages were homogenized by sonication and the TF activity was determined using two commercial chromogenic kits with the same assay principle (Actichrome TF; American Diagnostica, Stamford, Connecticut, USA) for IgG results and (AssaySense TF; Assaypro) for IgM results. The data of TF activities were normalized using the protein concentration as reference and expressed in pM/mg/mL.
Tissue factor expression by ex vivo quantum dot nanocrystals and dual photon excitation laser scanning microscopy in peritoneal macrophages
C6 À/À mice or their corresponding wild-type were injected in groups of two, with IgG-APS or with IgM-APS or with the corresponding controls IgG-NHS or IgM-NHS. In addition, C6 À/À and C3H/ HeJ mice were injected with 100 mg lipopolysaccharide (LPS; Sc-3535 Santa Cruz Biotechnology) as a positive control or with sterile PBS (GIBCO, Invitrogen TM ) as a negative control, four hours before euthanasia.
Peritoneal macrophages were obtained after euthanasia by washing the peritoneal cavity with 5 mL of Dulbecco's Modified Eagle Medium (DMEM, GIBCO, Grand Island, New York, USA) supplemented with polymyxin B (final concentration 20 mg/mL). The liquid obtained from the peritoneal cavity was centrifuged at 500 g for 10 min at 4 C. The pellet obtained was suspended in 50 mL of ice-cold DMEM and then the cell suspension was placed on a sterile slide and into a sterile Petri plate, subsequently covered and incubated at 37 C at 5% CO 2 for 60 minutes to allow the adherence of macrophages on surface. Nonadherent cells and medium were removed and washed twice with 1 mL of PBS, then cells were fixed with Buffered Formalde-Fresh 4% (Fischer Scientific) for 10 minutes at room temperature. The preparations were finally washed twice with 1 mL of PBS and they were blocked with PBS-2% bovine serum albumin (BSA, SIGMA) free proteases for 30 minutes at room temperature to avoid non-specific binding. 19 The quantum dot immunolabeling of the TF was carried out by treatment of the preparations first with a primary antibody (rabbit anti-mouse tissue factor IgG (American Diagnostica)) diluted in PBS-2% BSA (1 : 100 dilution) for 1.5 hours and subsequently incubated with a goat antirabbit IgG conjugated with Qdot 655 (Molecular Probes, Eugene, Oregon, USA). Staining of the nuclei was done by applying a Hoechst stain (2 : 1000 in PBS, Molecular Probes). 40, 41 Images of Qdot fluorescence were obtained using a custom built 2-photon microscope consisting of a Zeiss 410 LSM 2-photon excitation laser scanning microscope, equipped with a near-infrared titanium-sapphire femto second laser (Spectra Physics) that was tuned and mode-locked at 750 nm. An image analysis program Metamorph software (Molecular Devices) was used to measure the average fluorescence intensity in several cells.
Statistical analyses
All statistical analyses were done using SIGMA STAT version 3.5 software (Systat Software, Inc.) All data are represented as means AE standard deviation (SD). Comparisons between the study groups were performed with one way analysis of variance (ANOVA), followed by Tukey's test for TF activity in carotid artery homogenates, TF expression in murine peritoneal macrophages and thrombus size. P values of less than 0.05 were considered statistically significant.
Results

Characterization of the immunoglobulins used to inject the mice
First, we determined the titers of aCL and ab 2 GPI in the Ig preparations. The IgG-APS1, IgG-APS2 fractions injected in the mice had high positive titers of aCL (135, 123 GPL), ab2GPI (145, 120 SGU) antibodies, respectively. The IgM-APS fraction was high positive for aCL (159 MPL) and ab2GPI (100 SMU) antibodies, respectively. The controls IgG-NHS and IgM-NHS were negative for aCL (<10) and ab 2 GPI (<20) antibodies. Then, we examined the ability of the IgG preparations to fix complement after binding to b 2 GPIcoated plates, as described in the methods section. The results were expressed in OD units as mean AE SD, OD value >0.3 was considered as positive. While IgG-APS 1 (0.857 AE 0.03), IgG-APS2 (0.948 AE 0.05) and IgM-APS (0.745 AE 0.07) fractions fixed C1q after binding to b 2 GPI, IgG-NHS (0.153 AE 0.04) and IgM-NHS (0.202 AE 0.07) did not. C6 À/À mice are protected from the thrombogenic effects of aPL antibodies At the time of the surgical procedures the mice injected with IgG-APS or IgM-APS, whether C6 deficient or not, had medium to high titers of aCL and ab 2 GPI antibodies, (>40 GPL/MPL and >40SGUL/SMU, respectively) ( Table 1) .
Then, we looked at the thrombogenic effects of IgG isolated from APS patients in mice lacking C6. Thrombus sizes were significantly larger in C6 þ/þ treated with IgG-APS1 or IgG-APS2 when compared with C6 þ/þ mice treated with IgG-NHS (p < 0.001, and p ¼ 0.001, respectively). Importantly, the thrombus size was partially but significantly smaller in C6 À/À mice injected with IgG-APS1, IgG-APS2 compared to their C6 þ/þ counterparts (p < 0.001, p ¼ 0.009) (Figure 1 ). Mice lacking C6 injected with IgG-APS1 or IgG-APS2 had larger thrombi compared to the same mice (C6 À/À ) injected with IgG-NHS, (p ¼ 0.005 and p ¼ 0.002, respectively), indicating that the lack of C6 protected the mice partially from IgG-APSinduced thrombophilia.
IgM antibodies are known to fix complement with high avidity. Hence, we examined the thrombogenic effects of an IgM isolated from a patient with confirmed APS (IgM-APS), that was only positive for IgM aCL and ab 2 GPI antibodies. Similarly to what was observed with IgG-APS, C6 þ/þ mice injected with IgM-APS had larger thrombi when compared to the same type of mice injected with IgM-NHS (p < 0.001). Importantly, the thrombus sizes in mice lacking C6 treated with IgM-APS were significantly smaller compared to the ones seen in the C6 þ/þ strain (p < 0.001) ( Figure 2 ). Tissue factor activity induced by IgG-APS is diminished in C6 À/À mice
We measured the TF activity on the monocytes and carotids harvested from the experimental animals injected with IgG-APS1, IgM-APS, IgG-NHS or IgM-NHS. The TF activities in carotid artery homogenates and in peritoneal macrophages in C6 þ/þ mice after the treatment with IgG-APS were significantly higher compared to the activities seen in the same type of mice treated with IgG-NHS (p ¼ 0.013 and p ¼ 0.010, respectively) ( Table 2 ). The TF activities in carotid artery homogenates and in peritoneal macrophages in C6 þ/þ mice after the treatment with IgM-APS were also significantly higher compared to the activities seen in the same type of mice treated with IgM-NHS (p < 0.050 for both) ( Table 2) In contrast, C6 À/À mice injected with Five animals per group were injected intraperitoneally (i.p.) with 500 mg of IgG-APS1 or with IgG-APS2 or with IgG-NHS twice, as described in the methods section. Thrombus formation was studied after 72 hours of the first injection. APS: antiphospholipid syndrome; C6 þ/þ : C3H/HeJ; NHS: normal human serum. *Statistically significant difference between C6 À/À mice treated with IgG-APS1, IgG-APS2 vs C6 þ/þ mice treated with IgG-APS1, IgG-APS2 respectively (p < 0.001), (p ¼ 0.009). **Statistically significant difference between C6 þ/þ mice treated with IgG-APS1, IgG-APS2 vs C6 þ/þ mice treated with IgG-NHS respectively (p < 0.001 and p ¼ 0.001, respectively). ô Statistically significant difference between C6 À/À mice treated with IgG-APS1 vs C6 À/À mice treated with IgG-NHS (p ¼ 0.005). ôô Statistically significant difference between C6 À/À mice treated with IgG-APS2 vs C6 À/À mice treated with IgG-NHS (p ¼ 0.002). Tissue factor expression in peritoneal macrophages is reduced in C6 À/À mice after treatment with IgG-APS Macrophages were isolated from the peritoneal cavities of the experimental animals after treatment with IgG-APS1, IgG-APS2 or with IgG-NHS or with LPS or with PBS. TF expression in the macrophages was examined ex vivo as described in the methods section using Qdot nanocrystals and dual photon excitation scanning microscopy. Wild-type mice treated with LPS or with IgG-APS1, IgG-APS2 expressed significantly larger amounts of TF on the surface of the macrophages when compared with C6 þ/þ mice injected with PBS (p < 0.001). In addition, C6 þ/þ mice had significantly larger amounts of TF when compared to same type of mice injected with control IgG-NHS (p < 0.001). C6 À/À mice treated with LPS expressed significantly larger amounts of TF on the surface of the macrophages when compared with C6 À/À mice injected with PBS (p < 0.001). Importantly, TF expression induced by IgG-APS1 was significantly diminished in C6 À/À mice compared between C6 þ/þ mice treated with IgG-APS1 (p < 0.001). However this effect was only partial, since the TF expression in C6 À/À mice treated with IgG-NHS was significantly lower when compared to C6 À/À mice treated with IgG-APS 1 or with IgG-APS2 (p < 0.001) (Figure 3 ).
Discussion
In these studies we demonstrate for the first time that thrombogenic effects of human IgG and IgM from APS patients were significantly diminished in mice that lack C6 and that are subsequently not able to assemble the membrane attack complex, indicating that C5b-9 MAC is involved in aPLmediated pathogenic effects in vivo. Several studies have shown upregulation of TF in monocytes and EC in vitro and in vivo by aPL antibodies. It is now accepted that TF is a prothrombotic biomarker in APS. 7, 11, [12] [13] [14] [15] Importantly, in our studies the decrease in the thrombogenic effect produced by aPL antibodies in C6 deficient mice, was associated with a significant lowering of TF activity in carotid arteries and in macrophages. In addition, the effects of aPL antibodies and controls in the various strains of mice were also studied ex vivo in experiments where TF expression was measured using quantum dot nanocrystal and dual photon excitation laser scanning microscopy, an innovative and state-of-the art technique that enables to determine not only the distribution but also the quantitation of the TF expression in the surface of the cells obtained from the mice. [40] [41] [42] [43] The hypothesis that complement activation plays a role in the pathogenesis of aPL antibodies is based on aPL-complement fixing antibodies. Human IgMs are known to fix complement efficiently. However, human IgG subclasses differ in their capacity to fix and activate complement through the classical pathway, IgG4 being nonfixing complement antibodies. Studies have shown that approximately 70-80% of aCL antibodies in APS patient sera are able to fix complement. 44 Hence it is possible that not all IgG-APS will fix complement. In a previous study, we showed that C5aR deficient mice were protected from thrombophilia and EC activation in vivo, only when mice were injected with IgM-APS but not when a non-complement fixing IgG-APS was used. 32 Table 2 Tissue factor (TF) activity in C6 deficient À/À (C6 À/À ) mice is abrogated after the treatment with IgG-APS1 or IgM-APS Statistically significantly different from C6 À/À mice treated with IgG-APS1 vs C6 þ/þ mice treated with IgG-NHS (p ¼ 0.01 for TF in carotid artery homogenates and for TF in peritoneal macrophages) ôôô Statistically significantly different from C6 À/À mice treated with IgM-APS vs C6 þ/þ mice treated with IgM-APS (p < 0.050 for TF in carotid artery homogenates and for peritoneal macrophages) ôôôô Statistically significantly different from C6 À/À mice treated with IgG-APS1 vs C6 þ/þ mice treated with IgG-NHS (p < 0.050 for TF in peritoneal macrophages).
In agreement with that study, here we showed that the abrogation of pathogenic effects (thrombosis and TF upregulation) was seen in mice lacking C6 that were injected with either IgM-APS or with any of the two IgG-APS, both of which showed C1qbinding activity to b 2 GPI-coated plates.
The animal model of induced thrombosis utilized in these studies has proven over the years to be effective in testing the pathogenic effects of human and mouse monoclonal and polyclonal aPL antibodies in different strains of mice, including several types of knock-out animals. 3, 6, 10, 16, 19, 20, 21, 30, 32, 38 In addition, human aPL antibodies can be used in mice since the amino acid sequence and structure of human and mice b 2 GPI, the major antigenic target of aPL antibodies, are highly homologous. 45 Interestingly, hypocomplementemia has been found in a significant proportion of patients with primary APS and was associated with thrombosis in one study and with livedo reticularis and thrombocytopenia in another publication. [46] [47] [48] Recent studies have suggested that activation of the complement cascade is necessary for aPLmediated thrombophilia and fetal loss. [29] [30] [31] [32] [33] [34] First, in a study by our group, we found that inhibition of the complement cascade in vivo, using the C3 convertase inhibitor complement receptor 1-related gene protein y (Crry)-Ig, blocks aPL-induced fetal loss and growth retardation and inhibits aPLmediated thrombosis. 31 Furthermore, mice deficient in complement C3 and C5 (C3 À/À and C5 À/À , respectively) were resistant to thrombosis, EC ô Statistically significantly different from C6 þ/þ mice injected with IgG-APS1, IgG-APS2 vs C6 À/À mice injected with IgG-APS1, IgG-APS2 (p < 0.001). ôô Statistically significantly different between C6 À/À mice injected with IgG-APS1, IgG-APS2 and C6 À/À mice injected with IgG-NHS (p < 0.001).
activation and fetal loss induced by aPL Abs. 30 Furthermore, an anti-C5 monoclonal antibody reversed the thrombogenic properties of aPL antibodies in vivo, thus confirming involvement of C5 complement activation in aPL-induced thrombosis. 30 It has also been shown that the interaction of complement component 5a (C5a) with its receptor (C5aR) is necessary for thrombosis of placental vasculature. 33 Then, it was concluded that complement activation is a necessary intermediary event in the pathogenesis of thrombosis and fetal loss associated with aPL antibodies. These findings were confirmed in rats by Fischetti et al. who showed that thrombus formation induced by rat antibodies to b 2 GPI requires a priming factor such as bacterial LPS and is complement dependent. 37 We propose the following mechanism to explain the pathogenic effects of aPL antibodies on thrombosis. First, aPL antibodies bind directly to EC and other target cells such as monocytes and platelets and induce their activation and a procoagulant state, as demonstrated in vivo and in vitro studies. These include upregulation of adhesion molecules and TF expression. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] APL antibodies also induce platelet activation and interact with elements of the coagulation cascade. 12 Interestingly, and in agreement with that proposal, in these studies the abrogation of the thrombogenic effects and of the TF upregulation by the two IgG-APS in C6 deficient mice, though statistically significant, was incomplete, indicating that other pathogenic mechanisms are involved, most likely due to the direct effects of aPL antibodies through receptor(s) in target cells, as described. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Then, activation of the complement cascade by aPL antibodies may amplify these effects by stimulation of the generation of potent mediators of platelet and EC activation, including C5b-9 MAC. Proinflammatory and prothrombotic effects of sublytic concentrations of C5b-9 MAC have shown in numerous studies. 38, 49 In addition, sublytic C5b-9MAC has been shown to stimulate the expression of TF on EC which triggers a prothrombotic state through a factor VIIdependent pathway. 23, 50, 51 Promotion of coagulation is another effect exerted by the complement system on the endothelium and altogether these studies underscore the link between complement activation and thrombophilia in inflammatory diseases. Hence, It can be hypothesized that all those proinflammatory and prothrombotic effects of C5b-9 MAC may enhance the direct effects of aPL antibodies on target cells such as EC, monocytes and platelets and contribute to the thrombotic diathesis observed in APS.
In summary, the findings from this study underscore for the first time a novel pathogenic mechanism mediated by aPL antibodies involving the C5b-9 MAC and opens the possibility of utilizing complement system inhibitors for the treatment of clinical manifestation of APS, pending the successful completion of clinical studies.
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